Inadequate awareness among chronic kidney disease patients regarding food and drinks containing artificially added phosphate

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Shutto, Yoshiko ^a   Shimada, Michiko ^b   Kitajima, Maiko ^b   Yamabe, Hideaki ^b   Saitoh, Yoko ^c   Saitoh, Hisao ^c   Razzaque, Mohammed S ^d  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c Hirosaki Hospital   (Japan)

^d HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; CARBONATED BEVERAGES; CASE-CONTROL STUDIES; FEMALE; FOOD HABITS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PHOSPHATES; QUESTIONNAIRES; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 84893546415     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078660     Document Type: Article

References (31)

1. Razzaque MS (2011) Phosphate toxicity: new insights into an old problem. Clin Sci (Lond) 120: 91-97.
2. Econs MJ (1999) New insights into the pathogenesis of inherited phosphate wasting disorders. Bone 25: 131-135.
3. Razzaque MS (2011) Osteo-renal regulation of systemic phosphate metabolism. IUBMB Life 63: 240-247.
4. Snively CS, Gutierrez C (2004) Chronic kidney disease: prevention and treatment of common complications. Am Fam Physician 70: 1921-1928.
5. Razzaque MS (2009) The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 5: 611-619.
6. Terai K, Nara H, Takakura K, Mizukami K, Sanagi M, et al. (2009) Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Br J Pharmacol 156: 1267-1278.
7. Razzaque MS (2009) FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol Renal Physiol 296: F470-476.
8. Ohnishi M, Razzaque MS (2010) Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 24: 3562-3571.
9. Razzaque MS (2011) The dualistic role of vitamin D in vascular calcifications. Kidney Int 79: 708-714.
10. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, et al. (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528.
11. Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, et al. (2010) Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol 5: 2251-2257.
12. Kanbay M, Goldsmith D, Akcay A, Covic A (2009) Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif 27: 220-230.
13. Block G, Port FK (2003) Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. Semin Dial 16: 140-147.
14. Hruska K, Mathew S, Lund R, Fang Y, Sugatani T (2011) Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? Kidney Int Suppl: S9-13.
15. Fukagawa M, Hamada Y, Nakanishi S, Tanaka M (2006) The kidney and bone metabolism: Nephrologists' point of view. J Bone Miner Metab 24: 434-438.
16. Ohnishi M, Nakatani T, Lanske B, Razzaque MS (2009) In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. Circ Cardiovasc Genet 2: 583-590.
17. Ohnishi M, Nakatani T, Lanske B, Razzaque MS (2009) Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int 75: 1166-1172.
18. Nakatani T, Sarraj B, Ohnishi M, Densmore MJ, Taguchi T, et al. (2009) In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) - mediated regulation of systemic phosphate homeostasis. FASEB J 23: 433-441.
19. Nakatani T, Ohnishi M, Razzaque MS (2009) Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J 23: 3702-3711.
20. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, et al. (2007) High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 22: 2909-2916.
21. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, et al. (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503-511.
22. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, et al. (2004) Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19: 179-184.
23. Shutto Y, Shimada M, Kitajima M, Yamabe H, Razzaque MS (2011) Lack of awareness among future medical professionals about the risk of consuming hidden phosphate-containing processed food and drinks. PLoS One 6: e29105.
24. Molony DA, Stephens BW (2011) Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations. Adv Chronic Kidney Dis 18: 120-131.
25. Ahlenstiel T, Pape L, Ehrich JH, Kuhlmann MK (2010) Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease. Nephrol Dial Transplant 25: 3241-3249.
26. Sigrist MK, Chiarelli G, Lim L, Levin A (2009) Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review. J Ren Care 35 Suppl 1: 71-78.
27. Ketteler M, Biggar PH (2009) Dietary and pharmacological control of calcium and phosphate metabolism in predialysis stages of chronic kidney disease. Blood Purif 27: 345-349.
28. Barsoum RS (2006) Chronic kidney disease in the developing world.NEngl J Med 354: 997-999.
29. Tokunaga S, White IR, Frost C, Tanaka K, Kono S, et al. (2002) Green Tea Consumption and Serum Lipids and Lipoproteins in a Population of Healthy Workers in Japan. Ann Epidemiol 12: 157-165.
30. Osuka S, Razzaque MS (2012) Can features of phosphate toxicity appear in normophosphatemia? J Bone Miner Metab 30: 10-18.
31. Razzaque MS (2013) Phosphate toxicity and vascular mineralization. Contrib Nephrol 180: 74-85.